{"protocolSection": {"identificationModule": {"nctId": "NCT00942994", "orgStudyIdInfo": {"id": "CSPA100AUS02"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension", "officialTitle": "An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension", "acronym": "ASCENT"}, "statusModule": {"statusVerifiedDate": "2011-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-06"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-07-19", "studyFirstSubmitQcDate": "2009-07-20", "studyFirstPostDateStruct": {"date": "2009-07-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-03-29", "resultsFirstSubmitQcDate": "2011-03-29", "resultsFirstPostDateStruct": {"date": "2011-04-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-05-16", "lastUpdatePostDateStruct": {"date": "2011-06-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "Aliskiren", "Amlodipine", "HCTZ", "Systolic blood pressure", "Diastolic blood pressure", "Stage II", "Combination"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 412, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Triple Therapy (Aliskiren/Amlodipine/HCTZ)", "type": "EXPERIMENTAL", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg.", "interventionNames": ["Drug: Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)"]}, {"label": "Dual Therapy (Aliskiren/Amlodipine)", "type": "ACTIVE_COMPARATOR", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg.", "interventionNames": ["Drug: Aliskiren/Amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren/Amlodipine", "description": "Amlodipine capsule (5 mg)\n\nAliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)", "armGroupLabels": ["Dual Therapy (Aliskiren/Amlodipine)"]}, {"type": "DRUG", "name": "Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)", "description": "Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)\n\nHCTZ capsule (12.5 mg, 25mg)", "armGroupLabels": ["Triple Therapy (Aliskiren/Amlodipine/HCTZ)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8", "description": "To evaluate change from baseline in MSSBP after 8 weeks of treatment with an aliskiren, amlodipine, and HCTZ treatment regimen versus an aliskiren and amlodipine treatment regimen in minority patients with Stage 2 hypertension.", "timeFrame": "Baseline and week 8"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8", "description": "To evaluate change from baseline in MSDBP after 8 weeks of treatment with an aliskiren, amlodipine, and HCTZ treatment regimen versus an aliskiren and amlodipine treatment regimen in minority patients with Stage 2 hypertension.", "timeFrame": "Baseline and week 8"}, {"measure": "Percentage of Patients Achieving Blood Pressure Control (Defined as MSSBP < 140 mmHg and MSDBP < 90 mmHg) During 8 Weeks", "description": "To evaluate the cumulative percentage of patients achieving Blood Pressure control (defined as patients achieving an MSSBP \\<140 mmHg and MSDBP \\<90 mmHg) during 8 weeks of treatment with an aliskiren, amlodipine, and HCTZ treatment regimen versus an aliskiren and amlodipine treatment regimen in minority patients with Stage 2 hypertension. Cumulative refers to achieving BP control before or at the corresponding visit.", "timeFrame": "8 weeks"}, {"measure": "Percentage of Responders (Defined as Patients With MSSBP < 140 mmHg or a Reduction From Baseline in MSSBP of \u226520 mmHg) During 8 Weeks.", "description": "To compare the cumulative percentage of responders (defined as patients with MSSBP \\<140 mmHg or a decrease from baseline \u226520 mmHg) during 8 weeks of treatment with an aliskiren, amlodipine, and HCTZ treatment regimen versus an aliskiren and amlodipine treatment regimen in minority patients with Stage 2 hypertension. Cumulative refers to achieving a response before or at the corresponding visit.", "timeFrame": "8 weeks"}], "otherOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 2 and Week 4", "description": "Primary objective at additional timepoint.", "timeFrame": "Baseline, Week 2 and Week 4"}, {"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 2 and Week 4", "description": "Secondary objective at additional timepoint.", "timeFrame": "Baseline, Week 2 and Week 4"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who are newly diagnosed or have a history of hypertension, who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.\n* Men or women 18 years and older of minority background; self-identified.\n* Patients with stage 2 hypertension defined as MSSBP \u2265160 mmHg and \\<200 mmHg at Visit 5 (randomization).\n\nExclusion Criteria:\n\n* Patients with MSDBP \u2265110 mmHg and/or MSSBP \u2265200 mmHg as measured by office cuff at any visit.\n* Patients on 4 or more antihypertensive medications.\n* Patients with uncontrolled hypertension (MSSBP \\>180 mmHg) taking more than 1 antihypertensive medication at Visit 1.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "K and S Research Services", "city": "Little Rock", "state": "Arkansas", "zip": "72201", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Well Pharma Medical Research", "city": "South Miami", "state": "Florida", "zip": "33143", "country": "United States", "geoPoint": {"lat": 25.7076, "lon": -80.29338}}, {"facility": "Hyde Park Health Associates", "city": "Mattapan", "state": "Massachusetts", "zip": "02126", "country": "United States", "geoPoint": {"lat": 42.27232, "lon": -71.087}}, {"facility": "Manassas Clinical Research Center", "city": "Manassas", "state": "Virginia", "zip": "20110", "country": "United States", "geoPoint": {"lat": 38.75095, "lon": -77.47527}}, {"facility": "Scriber Kidney Center", "city": "Seattle", "state": "Washington", "zip": "98133", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}, "referencesModule": {"references": [{"pmid": "21414565", "type": "RESULT", "citation": "Ferdinand KC, Weitzman R, Israel M, Lee J, Purkayastha D, Jaimes EA. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. J Am Soc Hypertens. 2011 Mar-Apr;5(2):102-13. doi: 10.1016/j.jash.2011.01.006."}, {"pmid": "22305998", "type": "DERIVED", "citation": "Ferdinand KC, Weitzman R, Purkayastha D, Sridharan K, Jaimes EA. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension. J Am Soc Hypertens. 2012 May-Jun;6(3):219-27. doi: 10.1016/j.jash.2011.12.002. Epub 2012 Feb 3."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren / Amlodipine / HCTZ", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."}, {"id": "FG001", "title": "Aliskiren / Amlodipine", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "203"}, {"groupId": "FG001", "numSubjects": "209"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "187"}, {"groupId": "FG001", "numSubjects": "190"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "19"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren / Amlodipine / HCTZ", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."}, {"id": "BG001", "title": "Aliskiren / Amlodipine", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "202"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "411"}]}], "measures": [{"title": "Age Continuous", "description": "Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.7", "spread": "9.79"}, {"groupId": "BG001", "value": "54.7", "spread": "10.19"}, {"groupId": "BG002", "value": "55.2", "spread": "10.00"}]}]}]}, {"title": "Sex: Female, Male", "description": "Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "207"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "109"}, {"groupId": "BG002", "value": "204"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8", "description": "To evaluate change from baseline in MSSBP after 8 weeks of treatment with an aliskiren, amlodipine, and HCTZ treatment regimen versus an aliskiren and amlodipine treatment regimen in minority patients with Stage 2 hypertension.", "populationDescription": "Analysis was based on the Full Analysis Set consisting of all patients to whom study medication had been assigned. Last-observation-carried-forward was used. Baseline was not carried forward. In the Aliskiren/Amlodipine/HCTZ group, 5 patients did not have a post baseline measure. Hence, change from baseline to week 8 is reported for 197 patients.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and week 8", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine / HCTZ", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."}, {"id": "OG001", "title": "Aliskiren / Amlodipine", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"title": "Baseline [N=202, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "167.08", "spread": "7.277"}, {"groupId": "OG001", "value": "167.41", "spread": "7.118"}]}]}, {"title": "Week 8 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "130.73", "spread": "13.06"}, {"groupId": "OG001", "value": "137.87", "spread": "16.013"}]}]}, {"title": "Change from baseline to week 8 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "-36.43", "spread": "13.904"}, {"groupId": "OG001", "value": "-29.54", "spread": "15.674"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8", "description": "To evaluate change from baseline in MSDBP after 8 weeks of treatment with an aliskiren, amlodipine, and HCTZ treatment regimen versus an aliskiren and amlodipine treatment regimen in minority patients with Stage 2 hypertension.", "populationDescription": "Analysis was based on the Full Analysis Set consisting of all patients to whom study medication had been assigned. Last-observation-carried-forward was used. Baseline was not carried forward. In the Aliskiren/Amlodipine/HCTZ group, 5 patients did not have a post baseline measure. Hence, change from baseline to week 8 is reported for 197 patients.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and week 8", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine / HCTZ", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."}, {"id": "OG001", "title": "Aliskiren / Amlodipine", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"title": "Baseline [N=202, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.25", "spread": "8.985"}, {"groupId": "OG001", "value": "95.25", "spread": "8.342"}]}]}, {"title": "Week 8 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.10", "spread": "10.317"}, {"groupId": "OG001", "value": "83.17", "spread": "10.116"}]}]}, {"title": "Change from baseline to week 8 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.10", "spread": "9.707"}, {"groupId": "OG001", "value": "-12.08", "spread": "9.062"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Blood Pressure Control (Defined as MSSBP < 140 mmHg and MSDBP < 90 mmHg) During 8 Weeks", "description": "To evaluate the cumulative percentage of patients achieving Blood Pressure control (defined as patients achieving an MSSBP \\<140 mmHg and MSDBP \\<90 mmHg) during 8 weeks of treatment with an aliskiren, amlodipine, and HCTZ treatment regimen versus an aliskiren and amlodipine treatment regimen in minority patients with Stage 2 hypertension. Cumulative refers to achieving BP control before or at the corresponding visit.", "populationDescription": "Analysis was based on the Full Analysis Set (FAS) consisting of all patients to whom study medication had been assigned.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine / HCTZ", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."}, {"id": "OG001", "title": "Aliskiren / Amlodipine", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"title": "Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.5"}, {"groupId": "OG001", "value": "40.2"}]}]}, {"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.8"}, {"groupId": "OG001", "value": "57.4"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.7"}, {"groupId": "OG001", "value": "67.9"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Responders (Defined as Patients With MSSBP < 140 mmHg or a Reduction From Baseline in MSSBP of \u226520 mmHg) During 8 Weeks.", "description": "To compare the cumulative percentage of responders (defined as patients with MSSBP \\<140 mmHg or a decrease from baseline \u226520 mmHg) during 8 weeks of treatment with an aliskiren, amlodipine, and HCTZ treatment regimen versus an aliskiren and amlodipine treatment regimen in minority patients with Stage 2 hypertension. Cumulative refers to achieving a response before or at the corresponding visit.", "populationDescription": "Analysis was based on the Full Analysis Set (FAS) consisting of all patients to whom study medication had been assigned.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Responders", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine / HCTZ", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."}, {"id": "OG001", "title": "Aliskiren / Amlodipine", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"title": "Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "79.2"}, {"groupId": "OG001", "value": "72.2"}]}]}, {"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.1"}, {"groupId": "OG001", "value": "84.7"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.6"}, {"groupId": "OG001", "value": "91.9"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 2 and Week 4", "description": "Primary objective at additional timepoint.", "populationDescription": "Analysis was based on the Full Analysis Set consisting of all patients to whom study medication had been assigned. Last-observation-carried-forward was used. Baseline was not carried forward. In the Aliskiren/Amlodipine/HCTZ group, 5 patients did not have a post baseline measure. Hence, change from baseline is reported for 197 patients.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, Week 2 and Week 4", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine / HCTZ", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."}, {"id": "OG001", "title": "Aliskiren / Amlodipine", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"title": "Baseline [N=202, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "167.08", "spread": "7.277"}, {"groupId": "OG001", "value": "167.41", "spread": "7.118"}]}]}, {"title": "Week 2 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "138.35", "spread": "12.578"}, {"groupId": "OG001", "value": "143.77", "spread": "13.922"}]}]}, {"title": "Change from baseline to week 2 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.81", "spread": "12.640"}, {"groupId": "OG001", "value": "-23.64", "spread": "13.673"}]}]}, {"title": "Week 4 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "132.42", "spread": "12.027"}, {"groupId": "OG001", "value": "140.43", "spread": "13.961"}]}]}, {"title": "Change from baseline to week 4 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "-34.74", "spread": "12.145"}, {"groupId": "OG001", "value": "-26.98", "spread": "13.389"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 2 and Week 4", "description": "Secondary objective at additional timepoint.", "populationDescription": "Analysis was based on the Full Analysis Set consisting of all patients to whom study medication had been assigned. Last-observation-carried-forward was used. Baseline was not carried forward. In the Aliskiren/Amlodipine/HCTZ group, 5 patients did not have a post baseline measure. Hence, change from baseline is reported for 197 patients.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, Week 2 and Week 4", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine / HCTZ", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."}, {"id": "OG001", "title": "Aliskiren / Amlodipine", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"title": "Baseline [N=202, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.25", "spread": "8.985"}, {"groupId": "OG001", "value": "95.25", "spread": "8.342"}]}]}, {"title": "Week 2 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "84.26", "spread": "9.597"}, {"groupId": "OG001", "value": "86.24", "spread": "8.908"}]}]}, {"title": "Change from baseline to week 2 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.95", "spread": "8.569"}, {"groupId": "OG001", "value": "-9.01", "spread": "7.872"}]}]}, {"title": "Week 4 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.29", "spread": "9.177"}, {"groupId": "OG001", "value": "85.35", "spread": "9.567"}]}]}, {"title": "Change from baseline to week 4 [N=197, 209]", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.92", "spread": "8.891"}, {"groupId": "OG001", "value": "-9.91", "spread": "7.606"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "8 weeks", "description": "AEs were analyzed in the Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.", "eventGroups": [{"id": "EG000", "title": "Aliskiren / Amlodipine / HCTZ", "description": "At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg.", "seriousNumAffected": 0, "seriousNumAtRisk": 202, "otherNumAffected": 22, "otherNumAtRisk": 202}, {"id": "EG001", "title": "Aliskiren / Amlodipine", "description": "At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg.", "seriousNumAffected": 3, "seriousNumAtRisk": 209, "otherNumAffected": 18, "otherNumAtRisk": 209}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 209}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 209}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 209}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 209}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 202}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 209}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}